The collaboration grants Astellas an option to firstly negotiate an exclusive, worldwide license at the end of Phase Ib, with both Phase Ia and Phase Ib studies to be conducted by MD Anderson. The agreement also includes up to $26 million as an option premium and for research and development funding.
http://ift.tt/19OxJoH
http://ift.tt/19OxJoH
No comments:
Post a Comment